The Food and Drug Administration's approval of a pharmaceutical treatment for low sexual desire in women has launched a heated debate over the dangers and benefits of medicalizing sex.
Laura's Law could provide a middle ground between the old norm of total institutionalization and the new one of total abandonment. But the statute is struggling to reconcile forestalling tragedies with patients' rights.